Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis

被引：0
|
作者：
Gurwitz, David [1 ]
Newman, William [2 ]
机构：
[1] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[2] Univ Manchester, Dept Med Genet, Manchester M13 9PL, Lancs, England
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2008年 / 100卷 / 18期
关键词：
D O I：
10.1093/jnci/djn269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    Ramon y Cajal, T.
    Altes, A.
    Pare, L.
    del Rio, E.
    Alonso, C.
    Barnadas, A.
    Baiget, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 33 - 38
  • [22] Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients
    Alsulaiman, Abdullah
    Chu, Hoyin
    Al-Jumaan, Mohammed
    Alyahya, Mohammed
    Al Marzooq, Yousef
    Almulhim, Fatmah
    Vatte, Chittibabu
    Alnimer, Areej
    Almuhanna, Afnan
    Al-Ali, Amein
    AlDubayan, Saud H.
    PHARMACOGENOMICS, 2023, 24 (07) : 411 - 423
  • [23] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer Response
    Berry, Donald A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [24] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
    Nakamura, Yusuke
    Ratain, Mark J.
    Cox, Nancy J.
    Mcleod, Howard L.
    Kroetz, Deanna L.
    Flockhart, David A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16): : 1264 - 1264
  • [25] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
    Pharoah, Paul D. P.
    Abraham, Jean
    Caldas, Carlos
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) : 1263 - 1264
  • [26] CYP2D6 Genotype Should Not Be Used for Deciding About Tamoxifen Therapy in Postmenopausal Breast Cancer Reply
    Brauch, Hiltrud
    Schroth, Werner
    Goetz, Matthew P.
    Muerdter, Thomas E.
    Winter, Stefan
    Ingle, James N.
    Schwab, Matthias
    Eichelbaum, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (21) : 2755 - 2756
  • [27] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response
    Regan, Meredith M.
    Bouzyk, Mark
    Rae, James M.
    Viale, Giuseppe
    Leyland-Jones, Brian
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) : 1266 - 1267
  • [28] Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
    Damodaran, Solai Elango
    Pradhan, Suresh Chandra
    Umamaheswaran, Gurusamy
    Kadambari, Dharanipragada
    Reddy, K. Sathyanarayana
    Adithan, Chandrasekaran
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 75 - 81
  • [29] The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients
    Al-khalil, Wouroud Ismail
    Al-Salhi, Lana
    Rijjal, Sara
    Aljamali, Majd
    Youssef, Lama A.
    BMC CANCER, 2022, 22 (01)
  • [30] The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients
    Wouroud Ismail Al-khalil
    Lana Al-Salhi
    Sara Rijjal
    Majd Aljamali
    Lama A. Youssef
    BMC Cancer, 22
12345